Insmed's freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first ...

The closure, broken by Endpoints News on Thursday after speaking with two former employees, appears to have officially happened last week, though no public announcements were made. Rampart also ...

Pharmas will need to provide their latest stance on the Most Favored Nation drug pricing plans, while biotech finally gets a ...

Aside from the layoffs, InflaRx will deprioritize Gohibic, a COVID-19 antibody that was granted emergency use authorization ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...

The Beltway-based biopharma disputed the FDA’s conclusions regarding the data provided in its supplemental application for ...

A bevy of other companies also brought in money on Thursday, including Alveus Therapeutics, Diagonal Therapeutics, ...

While venture capital funding dipped to a six-year low in 2025, it nevertheless remained above pre-pandemic levels for ...

In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to BioSpace tallies. BioSpace ...

The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...

Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.